Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience

Table 3 Response during and after treatment with direct-acting antivirals

Response	Overall, n = 119	Genotype 1			Genotype 2 SOF + RBV n = 42
		DCV/ASV n = 43	LDV/SOF n = 66	OBV/PTV/r n = 10
HCV RNA < LLOQ during treatment1, n (%)	119 (100)	41 (100)	66 (100)	9 (90)3	42 (100)
HCV RNA < LLOQ after end of treatment1, n (%)	118 (98.3)	42 (97.6)	66 (100)	9 (90)3	42 (100)
SVR122, n (%)	109 (91.6)	35 (83.3)	64 (97)	9 (90)3	42 (100)
On-treatment failure, n (%)	1 (0.8)	1 (2.3)	0 (0)	0 (0)	0 (0)
Relapse, n (%)	8 (6.7)	6 (16.7)	2 (3)	0 (0)	0 (0)

¹LLOQ (lower limit of quantification) = 25 IU/ML;

²SVR: Sustained virologic response;

³One case lost to follow-up. DCV/ASV: Daclatasvir/asunaprevir; LDV/SOF: Ledipasvir/sofosbuvir; OBV/PTV/r: Ombitasvir/paritaprevir/ritonavir; RBV: Ribavirin.